IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3011% above fair value
$0.19+0.01 (+7.37%)
Close on Nov 17, 2026Market cap $19.43MP/E –Yield –
IGC Pharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
IGC Pharma's operating cash flow for the twelve months ending Mar 31, 2026 was -$5.94M. For fiscal 2025 it was -$4.80M. The highest annual figure on record is $564.85K in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | -$4.80M | – |
| FY2024 | Mar 31, 2024 | -$5.20M | – |
| FY2023 | Mar 31, 2023 | -$7.05M | – |
| FY2022 | Mar 31, 2022 | -$7.46M | – |
| FY2021 | Mar 31, 2021 | -$10.80M | – |
| FY2020 | Mar 31, 2020 | -$8.68M | – |
| FY2019 | Mar 31, 2019 | -$3.33M | – |
| FY2018 | Mar 31, 2018 | -$1.93M | – |
| FY2017 | Mar 31, 2017 | -$1.39M | – |
| FY2016 | Mar 31, 2016 | -$157.70K | – |
| FY2015 | Mar 31, 2015 | -$2.58M | – |
| FY2014 | Mar 31, 2014 | -$1.74M | -408.4% |
| FY2013 | Mar 31, 2013 | $564.85K | – |
| FY2012 | Mar 31, 2012 | -$5.02M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$1.22M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$1.22M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$2.09M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$1.41M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$730.00K | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$1.32M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$996.00K | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$1.75M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$526.00K | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$1.59M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$1.62M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$1.47M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$1.52M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$1.65M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$1.69M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$2.20M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$887.00K | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$2.42M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$2.30M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$1.85M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$2.51M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$1.85M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$2.46M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$3.99M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$1.99M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$2.24M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$1.57M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$2.87M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$1.15M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$1.33M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$316.00K | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$535.00K | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$958.00K | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$346.00K | -278.7% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$105.07K | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$521.93K | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$908.01K | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $193.66K | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | -$879.64K | – |
See a number that looks wrong?